NCI National Clinical Trials Network – Network Lead Academic Participating Site

NCI 国家临床试验网络 – 网络主导学术参与站点

• 批准号: 10579865
• 负责人: LAWRENCE E FLAHERTY
• 金额: $ 47.16万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-05 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10579865
• 关键词: Adult; Advisory Committees; Affect; American College of Radiology Imaging Network; Biological Markers; Cancer Center; Cancer Research Network; Clinical Research; Clinical Trials; Colon Carcinoma; Communities; Comprehensive Cancer Center; Data; Disease; Doctor of Medicine; Doctor of Philosophy; Eastern Cooperative Oncology Group; Enrollment; Evaluation; Faculty; Funding; Goals; Grant; Healthcare Systems; Image; Institution; Intervention; Intervention Trial; Lead; Leadership; Malignant Neoplasms; Manuscripts; Michigan; Minority; Minority Recruitment; Monitor; National Clinical Trials Network; Organ; Parents; Patient Care; Patient Education; Patients; Phase; Play; Population; Positioning Attribute; Principal Investigator; Protocols documentation; Publications; Qualifying; Research; Research Design; Role; Safety; Science; Site; Southwest Oncology Group; System; Translations; United States; Universities; Woman; clinical care; expectation; meetings; melanoma; member; mortality; multidisciplinary; novel therapeutics; participant enrollment; personalized cancer therapy; programs

Wayne State University (WSU)/ Karmanos Cancer Institute (KCI) has been an active institutional member of the cooperative group system since 1972, an NCI designated Comprehensive Cancer Center since 1978, and a parent institution Phase I (U01) since 1993. We have an active membership in the NCTN and have been an active LAPS since its inception in 2013 enrolling patients in network trials through the CTSU and using the CIRB for activation. We have enrolled over 5,500 patients onto NCTN clinical trials over the past forty years and over 250 patients have been enrolled onto interventional trials since 2014, meeting and exceeding accrual goals in a consistent manner. Since April 2014, we have opened 52 NCTN trials, including 8 Alliance, 13 ECOG-ACRIN, 17 NRG and 14 SWOG. All adult NCTN qualifying Phase II and III protocols have been submitted through the CIRB for activation since 2009. Over the years, our faculty members have played an important role in both the administrative and scientific functions of the NCTN. Since 2014, eight faculty members have held nineteen leadership positions in SWOG and ECOG-ACRIN as well as serving on NCI organ site Task Forces and Steering Committees. Since 2014, 13 faculty members have been authors or co-authors of 41 NCTN abstracts or manuscripts, and 7 faculty members have been PI or Co-PIs of 11 NCTN clinical trials. Our Cancer Center is a unique urban based center of research, patient care and education which is reflected in our recruitment of minorities (24%) and women (44%) onto intervention trials. Since our inception, the cancer programs of WSU/KCI have been organized as multidisciplinary disease programs built on the premise that multidisciplinary clinical research and care provides the best treatment option for patients with cancer. Accordingly, the translation of ideas into Network Group proposals and studies and the incorporation of NCI designated high-priority trials into the WSU/KCI treatment priorities have been easily facilitated. NCI funded trials have the highest priority for activation within our institution. Dr. Lawrence Flaherty, a SWOG member since 1988, the SWOG U-10 PI since 1996 and LAPS PI since 2013 will serve as the PI of this submission. He was the SWOG Melanoma Vice Chair from 1990 until 2011 and has been Chair of the SWOG Data Safety and Monitoring Committee since 2011. Anthony Shields, M.D., PhD. is the Project Director/Principal Investigator of the WSU/KCI LAPS serves on the NCI Colon Cancer Task Force, the ECOG-ACRIN Principal Investigator Committee, the Scientific Planning Committee, and the Nomination Committee. He is the co-chair of the Experimental Imaging Sciences Committee and the Biomarker Steering Committee.

韦恩州立大学(WSU)/卡马诺斯癌症研究所(KCI)一直是 1972年起实行合作组制度，1978年起被NCI指定为综合癌症中心，家长 机构第一阶段(U01)，自1993年以来。我们在NCTN中有活跃的会员资格，自那以来一直是活跃的圈数 它成立于2013年，通过CTSU招募患者参加网络试验，并使用CIRB进行激活。我们有 在过去的40年里，有5500多名患者参加了NCTN临床试验，有250多名患者参加了试验 自2014年开始进行干预试验，始终如一地实现和超过应计目标。自2014年4月以来，我们 已经开展了52项NCTN试验，包括8个联盟、13个ECOG-ACRIN、17个NRG和14个SWOG。所有成人NCTN资格赛 自2009年以来，通过CIRB提交了第二阶段和第三阶段议定书以供激活。多年来，我们的教职员工 成员在NCTN的行政和科学职能方面都发挥了重要作用。自2014年以来，有八个 教职员工在SWOG和ECOG-ACRIN担任过19个领导职务，并在NCI机构任职 现场工作队和指导委员会。自2014年以来，有13名教职员工是41本书的作者或合著者 NCTN的摘要或稿件，以及7名教职员工是11项NCTN临床试验的PI或Co-PI。我们的癌症 中心是一家独特的城市研究、病人护理和教育中心，这一点反映在我们的招聘 少数族裔(24%)和妇女(44%)参加干预试验。自我们成立以来，WSU/KCI的癌症项目已经 被组织为多学科疾病计划，建立在多学科临床研究和护理的前提下 为癌症患者提供最佳治疗选择。相应地，思想转化为网络群组 提议和研究以及将国家癌症研究所指定的高优先级试验纳入世界卫生组织/KCI的治疗优先事项 都是很容易促成的。NCI资助的试验在我们机构内具有最高的激活优先权。劳伦斯博士 Flaherty自1988年起成为SWOG成员，自1996年起担任SWOG U-10 PI，自2013年起担任SWOG U-10 PI，将担任 这个意见书。他在1990年至2011年期间担任SWOG黑色素瘤副主席，并一直担任SWOG Data主席 自2011年以来一直担任安全和监测委员会成员。安东尼·希尔兹，医学博士，博士是项目总监/首席调查员 WSU/KCI LAPS服务于NCI结肠癌特别工作组、ECOG-ACRIN首席研究员委员会、 科学规划委员会和提名委员会。他是实验成像科学的联合主席 委员会和生物标志物指导委员会。